title: An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
abstract: To test whether inactivated influenza vaccines distributed during the 2003-2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.
authors.affiliation: Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy. giuseppe.del.giudice@chiron.com
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Del Giudice
authors.forename: Anne Katrin
authors.initials: AK
authors.lastname: Hilbert
authors.forename: Roberto
authors.initials: R
authors.lastname: Bugarini
authors.forename: Ada
authors.initials: A
authors.lastname: Minutello
authors.forename: Olga
authors.initials: O
authors.lastname: Popova
authors.forename: Daniela
authors.initials: D
authors.lastname: Toneatto
authors.forename: Ines
authors.initials: I
authors.lastname: Schoendorf
authors.forename: Astrid
authors.initials: A
authors.lastname: Borkowski
authors.forename: Rino
authors.initials: R
authors.lastname: Rappuoli
authors.forename: Audino
authors.initials: A
authors.lastname: Podda
mesh_terms: D000276:Adjuvants, Immunologic; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011136:Polysorbates; D013185:Squalene / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit; D013185:Squalene